04/15/2026
A patient recently asked whether I’d inject PDGF (platelet-derived growth factor) after learning a friend had it done elsewhere.
It’s a fair question, and one that highlights a tension in aesthetic medicine right now: the pace of innovation versus the rigor of evidence.
I carry PDGF in my practice and use it topically after deep resurfacing procedures, where its role in promoting cell proliferation and healing is well supported. What I don’t do is inject it into soft tissue, because the FDA has not approved it for that purpose.
PDGF has a complicated regulatory history. It was approved in the 1990s for diabetic wound healing, removed due to a black box warning related to cancer risk, and has since returned for topical application. The injectable question remains unanswered by the evidence.
Regenerative medicine (such as peptides, growth factors, PRF, PRP) holds enormous promise. But promise and proof are different stages. Part of my responsibility as a double board-certified facial plastic surgeon is knowing when to adopt and when to wait.
Do you have any other questions about regenerative medicine? Drop them in the comments!